Background: Treatment with interferon-alfa has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events. Aim: To investigate the safety of peginterferon alfa-2b in 300 hepatitis B e antigen-positive patients with compensated liver disease. Methods: Patients were treated with peginterferon al...
